PLANTATION, Fla., July 22 /PRNewswire-FirstCall/ -- Viragen (Amex: VRA)
(OTC Bulletin Board: VGNI) today confirmed that its Swedish manufacturing
facility in Ersboda is on schedule to commence with the production of
Multiferon(TM) in September. The Company has been upgrading and expanding its
production capabilities as a result of a more aggressive business direction
for its natural human alpha interferon drug. The Company previously reported
that it expects to report data later this year from studies evaluating
Multiferon for the treatment of malignant melanoma.
"The combined manufacturing capabilities of our existing facility in Umea
with our new facility in Ersboda will provide us with the compliance and
capacity necessary to focus on our goal to make Multiferon the world's most
prescribed natural human alpha interferon," stated Viragen's CEO Mr. Charles
A. Rice. Construction of the Ersboda facility was completed earlier this year
and is currently undergoing validation required by the Swedish regulatory
authorities.
Mr. Rice added, "I plan to personally observe the resumption of production
activities in Sweden in September. With our current inventory of frozen
Multiferon, which has a longer expiry date than finished product, we are well
positioned to support our ongoing business as well as pending new activities."
About Viragen, Inc.:
Viragen is a biotechnology company specializing in the research,
development and commercialization of natural and recombinant protein-based
drugs designed to treat a broad range of viral and malignant diseases. These
protein-based drugs include natural human alpha interferon, monoclonal
antibodies and a peptide drug. Viragen's strategy also includes the
development of Avian Transgenic Technology as a biomanufacturing platform for
the large-scale, cost-effective production of therapeutic proteins.
Viragen is publicly traded on the American Stock Exchange (VRA).
Viragen's majority owned subsidiary, Viragen International, Inc., is publicly
traded on the Over-The-Counter Bulletin Board (VGNI). Viragen's key partners
and licensors include: Roslin Institute, Memorial Sloan-Kettering Cancer
Center, Cancer Research UK, University of Nottingham (U.K.), University of
Miami, America's Blood Centers and the German Red Cross.
For more information, please visit: http://www.Viragen.com
Viragen, Inc. Corporate Contact:
Douglas Calder, Director of Communications
Phone: (954) 233-8746; Fax: (954) 233-1414
E-mail: dcalder@viragen.com
The foregoing press announcement contains forward-looking statements that
can be identified by such terminology such as "expect," "potential,"
"suggests," "may," "will," "should," "could" or similar expressions. Such
forward-looking statements involve known and unknown risks, uncertainties and
other factors that may cause the actual results to be materially different
from any future results, performance or achievements expressed or implied by
such statements. In particular, management's expectations regarding future
research, development and/or commercial results could be affected by, among
other things, uncertainties relating to clinical trials and product
development; availability of future financing; unexpected regulatory delays or
government regulation generally; the Company's ability to obtain or maintain
patent and other proprietary intellectual property protection; and competition
in general. Forward-looking statements speak only as to the date they are
made. The Company does not undertake to update forward-looking statements to
reflect circumstances or events that occur after the date the forward-looking
statements are made.
SOURCE Viragen, Inc.
 back to top
Related links:
http://www.viragen.com
Photo Notes:http://www.newscom.com/cgi-bin/prnh/20010426/HSTH018LOGO-b
AP Archive: http://photoarchive.ap.org
PRN Photo Desk, photodesk@prnewswire.com
CONTACT:
Douglas Calder, Director of Communications,
Viragen, Inc., +1-954-233-8746, or fax, +1-954-233-1414, or
dcalder@viragen.com
|
